Sathyadeepak Ramesh, M.D. Ophthalmology - Ophthalmic Plastic and Reconstructive Surgery Medicare: Accepting Medicare Assignments Practice Location: 35 Clyde Rd Ste 104, Somerset, NJ 08873 Phone: 609-608-0142 Fax: 855-644-0469 |
Dr. Richard C Angrist, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1527 State Route 27, Suite 2600, Somerset, NJ 08873 Phone: 732-246-1050 Fax: 732-846-1440 |
Tasneem F Shamim, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1283 Route 27, Somerset, NJ 08873 Phone: 732-745-4844 Fax: 732-545-3423 |
Roopinder Grewal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 49 Veronica Ave, Suite 204, Somerset, NJ 08873 Phone: 732-565-1500 Fax: 732-565-1501 |
News Archive
Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Latino children who live in areas with higher levels of air pollution have a heightened risk of developing Type 2 diabetes, according to a new USC-led study.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
Healthcare staff need to challenge their own assumptions about what is 'normal' if they are to provide non-discriminatory care to autistic people, according to authors writing in the journal Learning Disability Practice.
› Verified 7 days ago